Skip to main content
    E

    eXoZymes, Inc. (EXOZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.92
    +0.09 (+2.35%)

    Market Cap: $35.64M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    eXoZymes, Inc. (EXOZ) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    eXoZymes reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$9.16M, operating cash flow was -$6.50M and free cash flow was -$6.67M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$2.24M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $9.72M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$70.07KN/A-750.8%-2563.5%-2909.1%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2021 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Revenue$0$0$70.07K$0$0
    Cost of revenue$3.64M$2.53M$596.17K$147.75K$59.41K
    Gross profit-$3.64M-$2.53M-$526.11K-$147.75K-$59.41K
    Research and development$3.71M$1.87M$527.48K$348.08K$454.45K
    Operating income-$9.72M-$5.93M-$1.80M-$1.33M-$1.29M
    Net income-$9.16M-$5.86M-$2.04M-$1.40M-$1.21M
    EBITDA-$9.39M-$5.73MN/A-$1.18M-$1.15M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$137.76K$0$0$0$0
    Gross profit-$926.43K-$1.13M-$830.72K-$1.11M-$845.17K-$1.07M-$613.92K-$860.03K-$546.10K-$731.61K-$390.04KN/A
    Operating income-$3.05M-$2.95M-$2.39M-$2.70M-$2.52M-$2.55M-$1.95M-$1.98M-$1.61M-$1.33M-$1.01M-$985.05K
    Net income-$2.24M-$2.88M-$2.37M-$2.66M-$2.29M-$2.36M-$1.86M-$1.84M-$1.66M-$1.36M-$1.01M-$1.10M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $326.23K by $2.71M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Total assets$5.97M$13.03M$3.56M$2.69M$2.35M
    Current assets$3.94M$10.82M$1.21M$1.47M$1.05M
    Cash and equivalents$3.04M$9.72M$66.53K$558.57K$547.81K
    Total liabilities$2.57M$2.61M$3.94M$1.31M$1.15M
    Short-term debt$326.23K$230.03K$224.99K$145.00K$133.49K
    Shareholder equity$3.40M$10.42M-$384.32K$1.37M$1.20M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$5.86M$7.98M$4.02M$5.97M$7.72M$9.68M$11.53M$13.03M$3.56M$4.05M$4.01M$3.56M
    Total liabilities$3.67M$4.33M$2.49M$2.57M$2.34M$2.44M$2.64M$2.61M$7.16M$6.32M$5.26M$3.94M
    Cash and equivalents$3.26M$5.65M$1.44M$3.04M$5.10M$6.99M$8.51M$9.72M$233.94K$158.24K$113.80K$66.53K
    Shareholder equity$2.19M$3.65M$1.53M$3.40M$5.37M$7.24M$8.88M$10.42M-$3.60M-$2.26M-$1.25M-$384.32K
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Operating cash flow-$6.50M-$8.51M-$1.18M-$1.26M-$1.59M
    Capital expenditures$169.92K$396.45K$288.71K$185.98K$422.59K
    Free cash flow-$6.67M-$8.90M-$1.47M-$1.44M-$2.01M
    Investing cash flow-$150.22K-$359.22K-$311.17K-$87.21K-$312.25K
    Financing cash flow-$27.71K$18.52M$1.00M$1.36M$2.31M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.22M-$1.64M-$1.52M-$1.97M-$1.86M-$1.54M-$1.13M-$5.71M-$541.52K-$2.54M$281.20K-$783.28K
    Capital expenditures$309.98K$1$57.60K$74.99K$13.31K$50.57K$31.05K$210.41K$0$37.24K$148.81K$109.74K
    Free cash flow-$2.53M-$1.64M-$1.58M-$2.05M-$1.87M-$1.59M-$1.16M-$5.92M-$541.52K-$2.58M$132.39K-$893.02K
    Last 12 quarters

    Frequently Asked Questions About EXOZ

    What is eXoZymes' annual revenue?

    eXoZymes reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is eXoZymes profitable?

    No. eXoZymes reported net income of -$9.16M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does EXOZ generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$6.50M minus capital expenditures of $169.92K produced free cash flow of -$6.67M.

    How much debt does eXoZymes have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $326.23K and cash and equivalents of $3.04M.